References
- Muggia FM, Rozencweig M. The trail from an inert elec-trode to a therapeutic solution. Cancer Treatment Reports, 1979 (September): 63: 1.
- Prestayko AW, Crooke ST, Carter SK (Editors). Cisplatin: current status and new developments. Academic Press, NY 1980: 1-527.
- Rosenberg B. In Cisplatin: current status and new devel-opments (AW Prestayko, ST Crooke, and SK Carter, Eds), Academic Press, NY 1980: 10.
- Bunn PA Jr, Canetta R, Ozols RF, Rozencweig M (Editors). Carboplatin: current perspectives and future direc-tions. WB Saunders, Philadelphia 1990: 1-381.
- Rozenweig M, von Hoff DD, Slavik M, Muggia FM. Cis-diamminedichloroplatinum (II): a new anticancer drug. Ann Intern Med 1977; 86: 803–812.
- Higby DJ, Wallace JH Jr, Albert D, Holland JF. Diamminedichloroplatinum in the chemotherapy of testicular tumors, J Urol 1974; 112: 100–104.
- Proceedings, IX International Symposium on Platinum Coordination Compounds in Cancer Therapy. Semin Oncol (supplement) 2004 (to be published).
- Fojo T. Critical Review Hematology/oncology (to be published).
- Safaei R, Howell SB. Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Ibid.
- Jamieson ER, Lippard SJ. Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 1999; 99: 2467–2498.